## MDT: Medtronic plc - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -2.6% below STRENGTH zone (3.0-6.0%); PEG 3.73 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($94.26)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 1)

**1. FDA posts Class I recall notice about Medtronic heart vent catheters**
- Source: MedTech Dive | 20251223T153953 | Bearish | Relevance: 100%
- The FDA has issued a Class I recall notice for Medtronic's DLP Left Heart Vent Catheters due to issues with shape retention and perforation injuries. Medtronic had previously initiated a customer notification and quarantine of the affected lots after receiving 41 complaints, including three serious perforation injuries. The company has since corrected the issue for newly manufactured lots, but acknowledged limited product availability.

**2. Medtronicâ€™s diabetes spinoff MiniMed files for IPO**
- Source: MedTech Dive | 20251222T160446 | Somewhat-Bearish | Relevance: 100%
- Medtronic's diabetes spinoff, MiniMed, has filed for an initial public offering, despite reporting a $198 million loss on sales of $2.72 billion in its 2025 fiscal year. The company aims to leverage its broad portfolio of insulin pumps and glucose sensors to generate more revenue per customer, positioning itself against more specialized competitors. However, MiniMed faces challenges with the profitable manufacturing and scaling of its Simplera CGM sensor, which has led to significant charges and a decline in U.S. insulin pump sales.

**3. Yousif Capital Management LLC Sells 10,883 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251223T135216 | Somewhat-Bullish | Relevance: 100%
- Yousif Capital Management LLC reduced its stake in Medtronic PLC (NYSE:MDT) by 3.8% during the third quarter, selling 10,883 shares and retaining 275,120 shares valued at approximately $26.2 million. Despite this, Medtronic reported strong third-quarter earnings, exceeding analyst expectations with EPS of $1.36 and revenue of $8.96 billion, and announced a quarterly dividend of $0.71 per share. Analysts generally maintain a "Moderate Buy" rating for MDT with a consensus target price of $109.94.

**4. Coho Partners Ltd. Lowers Holdings in Medtronic PLC $MDT**
- Source: MarketBeat | 20251223T094416 | Neutral | Relevance: 100%
- Coho Partners Ltd. significantly reduced its stake in Medtronic PLC by 42.9% in the third quarter, selling 222,564 shares and owning 296,319 shares valued at $28.22 million. Despite this, other institutional investors increased their holdings in Medtronic. The medical technology company reported strong third-quarter earnings, beating analyst estimates, and announced a quarterly dividend.

**5. Assenagon Asset Management S.A. Sells 29,384 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251223T081917 | Somewhat-Bullish | Relevance: 100%
- Assenagon Asset Management S.A. reduced its stake in Medtronic PLC by 46% during the third quarter, selling 29,384 shares and leaving it with 34,426 shares valued at $3.279 million. Despite this, Medtronic reported strong quarterly earnings, beating analyst expectations with an EPS of $1.36 and revenue of $8.96 billion, and declared a quarterly dividend of $0.71. Institutional ownership of Medtronic remains high at 82.06%, while analysts maintain a "Moderate Buy" rating with a consensus price target of $109.94.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-18 | Truist Securiti | $107 | $110 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-18 | Truist Securiti | main | Hold |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 6 ($0.53M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.8% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 3.7x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 3.73 signals overvaluation risk, limited margin of safety. Balance sheet: strong liquidity (2.4x). Analyst sentiment negative (1 target cuts vs 0 raises). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $125.0B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.73 |
| Forward P/E | 15.9 |
| Current P/E | 17.2 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 1.2% to -2.6% (-3.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 5.6pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.62), momentum weakening. RSI neutral at 42. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -2.59% (CS: 21) | Weak |
| RSI_14 | 42.4 | Neutral |
| MACD Histogram | -0.62 | Bearish |
| vs SMA20 | 0.967x | Below |
| vs SMA50 | 1.002x | Above |
| vs SMA200 | 1.068x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $97.42
- **Stop Loss:** $94.26 (3.2% risk)
- **Target:** $100.58 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 379
- **Position Value:** $36,922.18
- **Portfolio %:** 36.92%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate risk appetite in holiday-thinned conditions. VIX at 52-week lows suggests complacency, but modest breadth improvement and stable yields indicate underlying stability. Focus on quality positioning ahead of 2026 catalysts.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*